Evidence map›Paper›PMID 39789223›Full record

ArticleCommunications biology2025

Shaping current European mitochondrial haplogroup frequency in response to infection: the case of SARS-CoV-2 severity.

José Luis Cabrera-Alarcon, Raquel Cruz, Marina Rosa-Moreno, Ana Latorre-Pellicer, Silvia Diz de Almeida, Scourge Cohort Group, José A Riancho, Augusto Rojas-Martinez, Carlos Flores, Pablo Lapunzina and 3 more

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

José Luis Cabrera-AlarconCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, E-28029, Spain.ORCID http://orcid.org/0000-0003-2880-509X
Raquel CruzCentro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, E-28029, Spain.ORCID http://orcid.org/0000-0002-6964-8898
Marina Rosa-MorenoCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, E-28029, Spain.ORCID http://orcid.org/0009-0001-2868-6126
Ana Latorre-PellicerGrupo de Genética Clínica y Genómica Funcional, Facultad de Medicina, Universidad de Zaragoza, IIS Aragón, CIBERER-GCV02, E-50009, Zaragoza, Spain.ORCID http://orcid.org/0000-0002-4703-6620
Silvia Diz de AlmeidaCentro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, E-28029, Spain.ORCID http://orcid.org/0000-0003-2813-8928
Scourge Cohort Group
José A RianchoCentro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable.(CIBERFES) Instituto de Salud Carlos III, Madrid, E-28029, Spain.
Augusto Rojas-MartinezTecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, México.
Carlos FloresCentre for Biomedical Network Research on Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Pablo LapunzinaCentro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, E-28029, Spain.ORCID http://orcid.org/0000-0002-6324-4825
Fátima Sánchez-CaboCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, E-28029, Spain.ORCID http://orcid.org/0000-0003-1881-1664
Ángel CarracedoCentro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, E-28029, Spain.
José Antonio EnriquezCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, E-28029, Spain. jaenriquez@cnic.es.ORCID http://orcid.org/0000-0002-3671-2961

Funding

Fondation Leducq 17CVD04Human Frontier Science Program (HFSP) RGP0016/2018Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CB16/10/00282
6 · The paper itself

Abstract

The frequency of mitochondrial DNA haplogroups (mtDNA-HG) in humans is known to be shaped by migration and repopulation. Mounting evidence indicates that mtDNA-HG are not phenotypically neutral, and selection may contribute to its distribution. Haplogroup H, the most abundant in Europe, improved survival in sepsis. Here we developed a random forest trained model for mitochondrial haplogroup calling using data procured from GWAS arrays. Our results reveal that in the context of the SARS-CoV-2 pandemic, HV branch were found to represent protective factors against the development of critical SARS-CoV-2 in an analysis of 14,349 patients. These results highlight the role of mtDNA in the response to infectious diseases and support the proposal that its expansion and population proportion has been influenced by selection through successive pandemics.

Indexed as

COVID-19DNA, MitochondrialHaplotypesSARS-CoV-2EuropeGenome-Wide Association StudyHumansMaleMitochondriaSeverity of Illness IndexDNA, Mitochondrial

Identifiers

PMID39789223
PMCPMC11718132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.